Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Toho Holdings Names Hiroyuki Kono as Next Chairman
April 30, 2015
- Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
- Boehringer Japan Pharma Sales Grow 3 Times Faster than Market in 2014
April 30, 2015
- Eliquis Shows Lower Incidence of Adverse Events Including Major Bleeding in PIII Study in Patients with Acute VTE
April 28, 2015
- Lixiana Recommended for European Approval by CHMP: Daiichi Sankyo
April 28, 2015
- Sanofi Files Primaquine for Vivax Malaria, Ovale Malaria in Japan
April 28, 2015
- Novartis Seeks Japan Approval for 2 Malignant Melanoma Drugs Transferred from GSK
April 28, 2015
- Eisai, Nihon Medi-Physics Tie Up for Diagnosis, Treatment of Dementia with Lewy Bodies
April 28, 2015
- Opdivo Gains Positive CHMP Opinion for Advanced Melanoma
April 27, 2015
- Takeda’s Shonan Lab Collaborative Research Initiative Forging Ahead
April 27, 2015
- Janssen Files Risperdal for Irritability Associated with Autistic Disorder in Children
April 27, 2015
- Eisai Launches 2 Anticancer Agents in Mexico
April 27, 2015
- Bayer Seeks Japan Approval of Prostate Cancer Drug Radium-223 Dichloride
April 27, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Astellas Sees 59% Rise in FY2014 Operating Profit
April 24, 2015
- Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US
April 24, 2015
- Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”
April 24, 2015
- Astellas Links Up with US Biotech Potenza on Immuno-Oncology
April 23, 2015
- Shionogi Ups FY2014 Earnings Outlook on ViiV Dividends
April 23, 2015
- Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…